Drug Use Evaluation of Clindamycin in Critical Care Units in Alexandria Main University Hospital

NCT05223400 | Completed FDA Drug

• 1 other identifier: 0305292
• Study Type: observational
• Target: 99
• Locations: 1 country
• Sites: 1

Brief Summary

Irrational use of antibiotics is a one of the main health system problems,it leads to antibiotic resistance,increasing antibiotics side effects and the total cost. This study is a medication use evaluation study aims to evaluate intravenous clindamycin prescribing practice in critical care units in Alexandria Main University Hospital.

Conditions

Infection, Bacterial

Outcome Measures

Primary Outcomes (1)

• the number of prescriptions with appropriate indications of clindamycin will be counted during the retrospective observation of all prescriptions

  appropriateness of clindamycin indication will be determined according to IDSA guidelines.

  1 month

Secondary Outcomes (5)

• the number of prescriptions with duplication of therapy with clindamycin will be counted during the retrospective observation of all prescriptions

  1 month

• the number of patients who had diarrhea as a main side effect of clindamycin

  1 month

• the number of patients who had severe drug interactions with clindamycin

  1 month

• Total clindamycin DDD defined daily doses and clindamycin defined daily doses per 1000 patients days.

  1 month

• to calculate the total cost of clindamycin.

  1 month

Interventions

Clindamycin Injection DRUG

it is a clindamycin use evaluation study

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All adult patients admitted to critical care units and on clindamycin emperical therapy .

You may qualify if:

• Adults 18 years old or more .
• Patients on clindamycin as an empirical treatment.
• Patients started clindamycin as an emperical treatment in other departments but the physician approved to continue it in critical care.

You may not qualify if:

• Children (less than 18 years old)
• Patients started clindamycin as a defenitive treatment (based on microbiological culture results).

Sponsors & Collaborators

• Alexandria University: lead

Study Sites (1)

Faculty of Mdicine

Alexandria, Egypt

Location

MeSH Terms

Conditions

Bacterial Infections

Interventions

Clindamycin

Condition Hierarchy (Ancestors)

Bacterial Infections and Mycoses; Infections

Intervention Hierarchy (Ancestors)

Lincomycin; Lincosamides; Pyrrolidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Glycosides; Carbohydrates

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: supervisor of clinical pharmacy unit in Alexandria Main University Hospital

Study Record Dates

• First Submitted: January 6, 2022
• First Posted: February 4, 2022
• Study Start: March 1, 2022
• Primary Completion: April 1, 2022
• Study Completion: April 1, 2022
• Last Updated: February 3, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will share

Locations

EG (1)